Artículo
Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients
Autor/es | Peña-Chilet, María
Esteban-Medina, Marina Muñoyerro Muñiz, Dolores Loucera, Carlos Villegas, Román López Miranda, José Rodríguez-Baño, Jesús Túnez, Isaac Bouillon, Roger Dopazo, Joaquín Quesada Gómez, José Manuel |
Departamento | Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2021-12-03 |
Fecha de depósito | 2022-11-28 |
Publicado en |
|
Resumen | COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of ... COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival study on a retrospective cohort of 15,968 patients, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Based on a central registry of electronic health records (the Andalusian Population Health Database, BPS), prescription of vitamin D or its metabolites within 15–30 days before hospitalization were recorded. The effect of prescription of vitamin D (metabolites) for other indication previous to the hospitalization was studied with respect to patient survival. Kaplan–Meier survival curves and hazard ratios support an association between prescription of these metabolites and patient survival. Such association was stronger for calcifediol (Hazard Ratio, HR = 0.67, with 95% confidence interval, CI, of [0.50–0.91]) than for cholecalciferol (HR = 0.75, with 95% CI of [0.61–0.91]), when prescribed 15 days prior hospitalization. Although the relation is maintained, there is a general decrease of this effect when a longer period of 30 days prior hospitalization is considered (calcifediol HR = 0.73, with 95% CI [0.57–0.95] and cholecalciferol HR = 0.88, with 95% CI [0.75, 1.03]), suggesting that association was stronger when the prescription was closer to the hospitalization. |
Agencias financiadoras | Consejería de Salud y Familias. Junta de Andalucía (COVID-011-2020; P18-RT-3471; PAIDI2020-DOC_00350) Ministerio de Ciencia e Innovación (PID2020-117979RB-I00) Instituto de Salud Carlos III (IMP/0019; ACCI2018/2; CB16/10/00245; CB16/10/0050; COV20/00788; PI19/00033) Programa H2020 de la Unión Europea. Beca Marie Curie Innovative Training Network "Machine Learning Frontiers in Precision Medicine" (813533) Fundación BBVA (G999088Q) |
Identificador del proyecto | COVID-011-2020
P18-RT-3471 PAIDI2020-DOC_00350 IMP/0019 ACCI2018/2 CB16/10/00245 CB16/10/0050 COV20/00788 PID2020-117979RB-I00 PI19/00033 813533 G999088Q |
Cita | Peña-Chilet, M., Esteban-Medina, M., Muñoyerro Muñiz, D., Loucera, C., Villegas, R., López Miranda, J.,...,Quesada Gómez, J.M. (2021). Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients. Scientific Reports, 11 (1), 23380. https://doi.org/10.1038/s41598-021-02701-5. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Real world evidence of calcifediol ... | 1.407Mb | [PDF] | Ver/ | |